“Moderna confronts a vocabulary dilemma in the Trump era, considering whether to rebrand its mRNA vaccines as "individualized neoantigen treatments" to navigate vaccine skepticism. This reflects how political and linguistic framing shapes biotech innovation and public acceptance of AI-designed therapeutics, potentially impacting the future of personalized medicine development.”